Apolipoprotein B, Immunogen Grade

Athens Research

Apolipoprotein B, Immunogen Grade

9

In Vitro Diagnostic, Cardiovascular Research, Diabetes Research, Antisera Production

Research Use Only

≥98% by SDS-PAGE; Single arc by IEP against whole human serum.

Apolipoprotein B-100

Apolipoprotein B (Apo B), the principal structural protein of LDL, VLDL, and chylomicrons, exists in two isoforms: Apo B-100 (4536 amino acids, liver-derived) and Apo B-48 (2152 amino acids, intestinal). Apo B-100 mediates LDL receptor binding, enabling cellular cholesterol uptake, while Apo B-48 facilitates dietary fat absorption via chylomicrons. Both isoforms stabilize lipoprotein particles and coordinate lipid transport through interactions with microsomal triglyceride transfer protein (MTP). Elevated Apo B levels (more then90 mg/100 mL) directly correlate with atherosclerotic cardiovascular disease (ASCVD) risk, outperforming LDL cholesterol as a predictor due to its one-to-one association with atherogenic particles. Mutations like APOB R3500Q cause familial hypercholesterolemia, impairing LDL receptor binding and increasing circulating LDL, leading to premature ASCVD. Apo B also contributes to insulin resistance and metabolic syndrome through pro-inflammatory pathways. Clinically, Apo B serves as a nonfasting biomarker for residual cardiovascular risk, guiding therapies like mipomersen, an antisense oligonucleotide that reduces Apo B synthesis and LDL levels in refractory hypercholesterolemia. Emerging applications include targeting Apo B in lipoprotein(a) reduction and hepatic steatosis management.

more then 1 year

Prepared from fresh, non-frozen plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.

-20C

41116100